Renalytix Plc (AIM:RENX)
3.300
-0.050 (-1.49%)
Mar 6, 2026, 12:12 PM GMT
Renalytix Revenue
In the fiscal year ending June 30, 2025, Renalytix had annual revenue of $3.00M USD with 30.43% growth. Renalytix had revenue of $522.00K in the quarter ending September 30, 2024, with 13.73% growth.
Revenue
$3.00M
Revenue Growth
+35.07%
P/S Ratio
6.69
Revenue / Employee
$65.22K
Employees
46
Market Cap
14.64M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.00M | 700.00K | 30.43% |
| Jun 30, 2024 | 2.30M | -1.10M | -32.41% |
| Jun 30, 2023 | 3.40M | 433.00K | 14.58% |
| Jun 30, 2022 | 2.97M | 1.48M | 99.20% |
| Jun 30, 2021 | 1.49M | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.03B |
| Smith & Nephew | 4.58B |
| Inspiration Healthcare Group | 45.20M |
| Cambridge Cognition Holdings | 9.05M |
| CelLBxHealth | 2.62M |
| Fusion Antibodies | 1.60M |
Renalytix News
- 1 year ago - Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US - GlobeNewsWire
- 1 year ago - Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination - GlobeNewsWire
- 1 year ago - Medicare Issues Final Coverage Determination for kidneyintelX.dkd - GlobeNewsWire
- 1 year ago - Renalytix Plc (RNLX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024 - GlobeNewsWire
- 1 year ago - Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15 - GlobeNewsWire
- 2 years ago - Renalytix Announces Financing with Expected Size of up to $4 Million - GlobeNewsWire
- 2 years ago - KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD) - GlobeNewsWire